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EDITORIAL REVIEW
The humoral immune response towards HLA class II
determinants in renal transplantation
Once a transplanted organ is exposed to the defense mecha-
nisms of a recipient, its survival is mainly determined by the
strength of the recipient's anti-donor immune response. Despite
potent immunosuppression, acute and chronic rejections account
for the majority of graft losses in recipients [1—3]. Most studies on
the immunopathogenesis of graft rejection concentrated on the
role of cell-mediated immune reactions and emphasized the
interaction of recipient T-cells with determinants of the major
histocompatibility complex (MHC) on donor cells [4—7].
According to numerous experimental studies, transplant rejec-
tion is in essence the result of cell-mediated cytotoxicity that can
be overcome by immunosuppression. In animals, even graft
tolerance is achieved by inhibition of cellular immunity [8].
Unfortunately, in humans the situation appears to be more
complicated. Clinical and histopathological observations docu-
ment a considerable heterogeneity with respect to severity and
type of rejections. While some acute rejections are responsive to
intensified immunosuppression, others follow a relentless course
despite vigorous treatment. Although graft biopsies are meticu-
lously assessed by pathologists, the correlation of histological
findings with clinical outcome remains limited [9]. Chronic rejec-
tion, characterized by the development of progressive vascular
occlusion and interstitial fibrosis, continues to be a major clinical
challenge. It does not respond satisfactorily to conventional
immunosuppression, and controversy exists as to the relative
contributions of alloantigen-dependent versus -independent fac-
tors in its pathogenesis [10, 11].
In this article we will address questions pertinent to the clinical
and immunopathogenic heterogeneity of transplant rejection. In
particular, we would like to focus the reader's attention on a few
selected aspects that we believe to be crucial for the assessment of
humoral immune reactions against HLA class II determinants.
Impact of the HLA-DR mismatch on graft survival
In every mammalian species studied, one set of closely linked
genetic loci determines the fate of allografts. The glycoproteins of
the human leukocyte antigen (HLA) system, encoded for by genes
on the short arm of chromosome 6, represent the human major
histocompatibility complex (MHC). Structural differences define
two classes of HLA molecules. Class I molecules (HLA-A, -B, -C)
consist of one polymorphic chain associated with j32-microglobu-
un. Class II molecules (HLA-DR, -DP, -DQ) consist of an a- and
a-chain. A characteristic, peptide-binding groove is formed by
each HLA molecule. With more than a hundred alternative forms
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of genes (alleles), the HLA complex is the most polymorphic
system known in man. Usually, the six HLA loci (A, B, C, DR, DP,
DO) derived from one chromosome are inherited together as a
haplotype [12]. Due to the enormous polymorphism of HLA, it is
highly unlikely for unrelated individuals to share an identical set
of molecules.
It is the basis of transplantation immunology that HLA mole-
cules are expressed on the cell surface and thus are accessible to
the immune system. The differences between donor and recipient
tissues, that is, the degree of incompatibility, can be expressed in
terms of "mismatches." It is safely established that the outcome of
transplanted cadaver donor kidneys correlates with the number of
HLA mismatches, resulting in a superior survival rate of well-
matched grafts [13]. However, further analysis of mismatches at
different HLA loci suggests, that not all loci are of equal impor-
tance. HLA-C was found to be irrelevant in early studies. Suffi-
cient data on the influence of the class II determinants DP and
DO are not yet available. Therefore, studies on the relative
importance of HLA loci in transplantation at present focus on the
class I determinants HLA-A and HLA-B, and the class II
determinant HLA-DR. The prime importance of HLA-DR is
illustrated by a direct comparison of grafts that, alternatively, have
complete matches at 2 HLA loci, combined with 0, 1 or 2
mismatches at the third locus (Fig. 1). Within these combinations,
mismatches at HLA-A show a minor, mismatches at HLA-B an
intermediate, and mismatches at HLA-DR a strong detrimental
effect on graft survival during the first year. It is interesting to note
that the HLA-DR impact is exerted already by 1 mismatch (Fig.
1C).
To elucidate the immunobiological role of HLA-DR in human
transplantation, a brief review of the essential function of HLA
molecules, their tissue distribution and the immunopathological
consequences thereof, is indicated.
Tissue distribution of alloantigens and immunogenicity of
graft endothelium
The HLA system and its polymorphism have evolved to secure
an individual's immunological identity, so that the immune system
can discriminate between self and non-self and combat invading
pathogens. As such, the effect of HLA in the artificial setting of
organ transplantation represents an accidental consequence of
this essential biological task [14].
Microorganisms residing in extracellular compartments are
readily accessible to the humoral immune system, that is, immu-
noglobulins and complement. Pathogens that manage to escape
humoral effector mechanisms, such as by entering host cells, have
to be attacked by cellular effectors. As a prerequisite, the immune
system must be informed of the presence of extra- or intracellular
pathogens. HLA molecules provide these informations at the cell
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Fig. 1. DiJfrrenual effects of mismatches (mn) at the l-ILA-A, -B, -DR loci
on survival of primaiy cadaver kidney grafts. (A) Minor effect of mismatches
at HLA-A (HLA-B + DR, mm = 0); (B) Intermediate effect of HLA-A
(HLA-A + DR, mm 0); (C) Strong effect of HLA-DR (HLA-A + B,
mm = 0), exerted already by 1 mismatch. Data source: Collaborative
Transplant Study. Symbols in A arc: ( ) HLA-A, mm = 0, N =
3151;( )HLA-A, mm = 1,N = 2382; (—.——-.--—.) HLA-A, mm =
2,N= 756. Symbols inBare:( )HLA-B,mm = 0,N= 3151;
) HLA-B, mm = 1; N = 2731; (—.—.—) HLA-B, mm = 2,
12 N = 790; Symbols in Care: ( ) HLA-DR, ram = 0, N = 3151;
) HLA-DR, mm = 1, N = 1220; (— —---) HLA-DR, mm =
2, N = 233.
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surface of phagocytes and infected host cells. They capture
peptides that are generated continuously inside the cells, trans-
port them to the cell membrane, and present them to the T-cell
receptor complex of circulating T-cells 1151. Thus, perpetual
identification of the presented HLA/peptide repertoire enables
the immune system to monitor the internal environment and
respond immediately when this repertoire is altered.
The limited number of allelic HLA variants within an individ-
ual, opposed by the virtually unlimited number of different
peptides, implies that one allelic variant can present various
peptides. Class I and class TI molecules acquire peptides from
separate compartments within a cell and use separate pathways of
processing and presentation (15]. Endugenous peptides derived
0 3 6 9
from protein degradation in the cytosol are presented primarily by
class I molecules to T-cells of CD8 type. Since representation of
the cytosolic compartment is obligatoiy to every cell, class I
determinants are expressed virtually on all somatic cells (Fig. 2A).
The class II pathway primarily involves processing of peptides
derived from endocytosed exogenous antigens and presentation to
T-cells of CD4 type. The association of class 11 molecules with the
specialized task of acquisition of exogenous antigens is reflected
by their restricted expression on privileged cells of the immune
system, such as phagocytic cells and antigen presenting cells
(APC), B-cells and activated T-cells [12]. It is important to note
that the expression in vivo of MHC class II determinants varies
among different species [161, dependent on the basal action of
-a —-
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Fig. 2. Distribution of HLA class land class II molecules in renal tissue. (A)
HLA class I molecules in normal kidney: expression on endothelial and
tubule cells (immunoperoxidase staining with mAb W.6.32); (B) Endothe-
hal expression of HLA-DR in normal kidney (staining with mAb L.2.43);
(C) Induced expression of HLA-DR in tubules during graft rejection(arrow); Note also presence of DR-positive cells within the cellular
infiltrates (mAb L.2.43; magnification >< 120). Publication of this figure in
color was made possible by a grant from Sandoz AG, Nurnberg, Germany.
cytokines such as IFN-y [17]. Thus, class 11 molecules are
normally expressed also on capillary endothelial cells in humans
(Fig. 2B), but not, for example, in rodents.
The interaction of T-cell receptors with self-MHC molecules
that harbor foreign peptides provides the basis of antigen-specific
T-cell activation in adaptive immunity. In the setting of transplan-
tation, however, recipient T-cell receptors, ignoring the rules of
thymic selection [18], recognize the foreign MHC molecules
themselves and give rise to strong T-cell activation. Recent studies
on alloreactivity have revealed that donor MHC molecules can be
recognized by recipient T-cells in at least two ways. In the direct
pathway, T-ccll receptors bind directly to intact MHC molecules
on donor cells without the help of APC. T-cell activation via the
direct pathway results in cell-mediated, cytotoxic immune reac-
tions. Alternatively, in the complex scenario of the indirect
pathway, donor MHC molecules are taken up by recipient APC
and subsequently are processed and presented as foreign peptides
within recipient MHC class II molecules to T-cells [191. Indirect
recognition can result in the generation of T-cell help (Thi) for
cell-mediated cytotoxic reactions, but also in help (Th2) for
alloantibody production by B-cells [20—221. The direct pathway of
recognition seems to operate predominantly during the early
phases of transplantation, whereas the indirect pathway is be-
lieved to play a role in later phases and possibly in chronic
rejection [23]. Both class I and class II molecules, preferably in
soluble form, are subject to indirect recognition in recipient
lymphoid organs, where abundant APC are available [24].
Since vascular endothehial cells within organ transplants form
the barrier between recipient and donor, they are the first
structures to be encountered by the recipient's immune reactants.
There is evidence that endothelial alloantigens can be recognized
in situ by both the direct and indirect pathway. Thus, allogeneic
human endothehium interacts with CD8 T-cells [25] and, depen-
dent on the presence of class II molecules, with CD4 T-cells [26].
Following antigen recognition, T-cells must receive co-stimulatory
signals in order to become fully activated. Lack of appropriate
co-stimulation can prevent T-cell activation and lead to anergy.
The signals required are best delivered by professional APC, such
as dendritic cells, via special accessory molecules. Endothelial
cells are likewise endowed with a variety of accessory molecules,
including ICAM-1 and LFA-3. Hence, graft endothelial cells can
initiate alloimmune responses [27], and although human endothe-
hum lacks the B7 accessory molecules, anergy is not induced in
responding CD4 lymphocytes [28].
Once rejection is in progress, inflammatory cytokines lead to
the up-regulation of HLA molecules and of additional adhesion
molecules on endothelial cells. Their combined expression adds to
the immunogenicity of blood vessels and also promotes the
recruitment of nonspecific bystander leukocytes from the circula-
tion [29]. Thus, endothehial cells can amplify inflammatory reac-
tions within a graft by the transient upregulation of certain
adhesion molecules. Cytokines also induce the de novo appear-
ance of HLA class 11 products and adhesion molecules at ex-
travascular sites, for example, on formerly negative tubule cells
(Fig. 2C) [30, 31]. The induced expression of these molecules in
adjacent tissue compartments, reflecting the spread of inflamma-
tion, further aggravates the immunological attack [321.
In summary, by displaying the full array of allogeneic HLA
molecules and of co-stimulatory adhesion molecules even under
normal conditions, the human endothelium is at center stage
during the various phases of transplant rejection [2, 33]. Con-
versely, the a priori absence of MHC class 11 molecules on rodent
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endothelia may provide an explanation for some of the discrep-
ancies between clinical results in patients and experimental results
in rodents.
Humoral immune response against transplanted organs
From an immunological point of view, a transplanted organ
may be regarded as a large extracellular pathogen. Given the
effectiveness of the indirect pathway of allorecognition with an
ensuing Th2-type response, humoral immune reactions directed
against alloantigens should be observed frequently. In addition, an
intense cross-talk between T- and B-cells is maintained within the
immune system [34]. Hence it would be surprising if a maximal
immunological challenge such as an organ transplant would act
exclusively upon T-cells.
There is abundant evidence that allogeneic HLA molecules are
strong inducers of humoral responses. In vivo, serum anti-
bodies against HLA are induced by multiple blood transfusions,
pregnancies, and also by previous organ grafts [35]. An analysis
of humoral immunity in transplant recipients therefore has to
consider two possible modes of sensitization: (1) pre-existing sens-
itization against alloantigens before transplantation; (2) develop-
ment of allosensitization against graft determinants after trans-
plantation.
That the humoral immune system per se has the potential to
reject and destroy grafts is manifested drastically by the phenom-
enon of hyperacute rejection. Preformed antibodies directed
against antigens of donor endothelium [35] enter the graft, and
activation of complement, coagulation factors and other media-
tors of inflammation results in endothelial damage, vascular
thrombosis and immediate graft loss [36]. A particular form of
accelerated rejection, showing 1gM and complement proteins
within areas of necrotizing arteritis and less often within peritu-
bular capillaries [37], was also attributed to preformed antibodies.
Hyperacute rejection has become extremely rare due to the
requirement of ABO compatibility and the introduction of cross-
match tests which preclude grafting into recipients with pre-
formed anti-donor antibodies.
In contrast to hyperacute and accelerated rejection, the contri-
bution of humoral immune mechanisms to the common, that is,
acute and chronic, forms of transplant rejection remains contro-
versial.
Currently, about 10 to 12% of patients awaiting first, and up to
45% of patients awaiting subsequent grafts have preformed
antibodies against alloantigens as measured in the lymphocyto-
toxicity panel-screening test. It is puzzling that these recipients
have more rejection episodes and lower graft survival rates than
unsensitized recipients, even though they had a negative cross-
match with their donor (Fig. 3A). Interestingly, preformed anti-
bodies appear to have the strongest impact on transplants with
mismatches at the HLA-DR locus (Fig. 3 B, C). The presence of
preformed antibodies could simply reflect a state of enhanced
overall immune reactivity. Alternatively, the standard crossmatch
technique may not be sensitive enough for the detection of low
level anti-donor antibodies. Such antibodies may, however, accu-
mulate in the graft without inducing hyperacute or accelerated
rejection. Evidence supporting this alternative will be provided
later in this article.
Less well recognized than the effect of presensitization is the
possible role of humoral sensitization in the post-transplantation
period, as it would apply not only to acute and chronic rejection,
but also to graft acceptance [38—40]. Relatively few studies have
addressed this important question. Post-transplant sensitization,
as defined by the de novo appearance of serum alloantibodies, was
reported in 56% of recipients of first renal allografts [41, 42]. The
generation of such antibodies directed against endothelial cells
[43], class 1 [44] and possibly class II determinants [40, 41, 45] was
clearly associated with chronic rejection and graft loss.
These serological results are, however, at variance with immu-
nohistological results obtained from transplant biopsies and ne-
phrectomies in the course of acute and chronic rejections. Immu-
noglobulin deposits are infrequently detected in biopsies during
acute cell-mediated rejection with infiltration of lymphocytes into
tubules and vessel walls. Therefore, immunofluorescence studies
are not considered to be particularly helpful in the assessment of
acute rejections [46]. Likewise, eluates from rejected grafts con-
tained little anti-HLA activity [47, 48]. The therapeutic success of
T-cell directed immunosuppression in many rejection episodes
further favored a predominantly cellular origin, and currently it is
widely believed that humoral immunity plays no role in acute
rejection. The pathogenesis of chronic rejection, characterized by
the development of progressive arteriosclerosis, glomerulosciero-
sis and interstitial fibrosis, is still obscure [49]. Immunofluores-
cence studies of biopsies yielded inconsistent results with regard
to the deposition of immunoglobulins and complement [46].
Eluates from kidney specimens variably contained antibodies with
reactivity against epitopes on T-cells, B-cells and endothelial cells
[50, 51]. However, the failure of conventional immunosuppressive
therapy entertained a continuous interest in the pathogenesis of
chronic rejection and a potential role of humoral immune re-
sponses against HLA therein. This issue was also addressed in
recipients of heart transplants with equivocal results, in that
contributing humoral immune mechanisms were reported in some
studies [52, 53, 54], whereas cellular mechanisms were empha-
sized in others [55].
Renewed interest in the role of humoral immune responses is
generated by clinical and experimental studies showing a contri-
bution of antibodies to both graft rejection and long-term accep-
tance. Protective antibodies could comprise anti-idiotypic anti-
bodies, that is antibodies that are induced by, and directed against
alloantibodies [52, 56, 57]. In experimental animals, the tolerizing
effect of donor specific blood transfusions was attributed recently
to an increased antibody response to donor MHC class II,
combined with a decreased response towards class I [58, 59]. The
complement system, a strong effector of humoral immunity, is also
being re-evaluated on the basis of a favorable graft outcome in
animals deficient for component C6 [60].
It can be concluded that the assessment of humoral immune
reactions in organ transplantation is surrounded by uncertainties,
and the role of pre-existing and developing allosensitization
remains ill-defined. However, there are indications that this
evaluation may have been incomplete. Especially the discrepan-
cies between serological and histological studies warrant close
attention.
Detection of humoral immune reactions in graft biopsies
The assessment of humoral anti-graft reactions appears to
depend critically on the examination of graft biopsies. Endothelial
HLA class I and class II molecules would be ideal targets for
humoral attacks due to their unique exposure. Thus, deposition of
immune reactants should occur primarily in arterial vessels and in
capillaries of the graft. Peritubular capillaries represent the most
extended vascular compartment within kidneys and are present in
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large numbers in every biopsy. However, widespread distribution
of immune deposits within the vasculature has been convincingly
demonstrated mainly in tissue slides reacted with eluates or serum
samples in vitro [43, 51], but infrequently in biopsy tissues derived
from transplants in vivo.
There are several issues that need to be considered in the
assessment of humoral immune reactions within blood vessels in
vivo. It is important to note that different pathogenetic mecha-
nisms may involve different target structures and that the detec-
tion of deposited antibodies depends on the turnover of the
antigen. For instance, antibodies or immune complexes that
deposit on a low-turnover structure such as basement membrane
may be retained for prolonged periods and produce bright
immunohistological findings (such as Goodpasture's syndrome).
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Fig. 3. impact of preformed "panel-reactive" serum antibodies in recipients
on the suivival of cadaver kidney grafts. The sera were tested against panels
of (unseparated) lymphocytes obtained from randomly selected blood
donors. (A) Panel-reactivity in % is significantly associated with graft
outcome (P < 0.0001). Symbols are: (- - - -) 0—10%, N = 79612; ()
11—50%, N = 7225; (— —-) 51—80%, N = 1896; ( ) > 80%, N =
1101. (B) >10% preformed antibodies, first transplants. Effect of HLA
mismatches on graft outcome in patients with substantial amounts
(>10%) of panel-reactive serum antibodies. In presensitized patients, the
effect of mismatching is greater than in nonsensitized patients. Differences
between 0 and 2 mismatched antigens for each of the 3 HLA loci: P <
0.0001. Symbols are: (- - - -) HLA-B, mm = 0, N = 1361; (.•..) HLA-A,
mm = 0, N = 1680; (— —) HLA-DR, mm = 0, N = 2351; (
HLA-A, mm = 2,N = 1693;(----)HLA-B,mm = 2, N = 1997;(—)
HLA-DR, mm = 2, N = 1064. (C) >10% preformed antibodies, retrans-
plants. When retransplantations are performed in presensitized recipients(>10% panel reactivity), the effect of HLA mismatches is very strong (P <
0.001 for each comparison of 0 versus 2 mismatches). Data source:
Collaborative Transplant Study. Symbols are: (-—• —-) HLA-DR, mm =
0,N=1884;(----)HLA-B,mm=0,N=1238;(")HLA-A,mm=0,N = 1574; ( )HLA-A, mm = 2, N = 802;(----)HLA-B, mm = 2,N = 1037; (—) HLA-DR, mm = 2, N = 586.
In contrast, anti-HLA antibodies are directed against surface
antigens of endothelial cells with a rapid turnover and such
antibodies are not readily detected by conventional techniques.
Following a humoral attack, endothelial cells rapidly remove
deposited immunoglobulins from the cell membrane by shedding
(Fig. 4A) and/or internalization [61, 62]. Furthermore, endothelial
cells can inhibit activation of complement at early and late stages
through the action of membrane cofactor protein (MCP), decay-
accelerating factor (DAF) or CD59. In concert with control
proteins from the circulation, complement proteins are rapidly
degraded and permanent deposition on the eel! surface is pre-
vented (Fig. 4B) [63—66]. Thus, antibodies binding to endothelial
surface antigens and most complement components will be de-
tectable only transiently in capillaries. According to experimental
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Fig. 4. Evasion strategies of endothelial cells. (A)
Removal of antibodies by shedding; (B)
Inhibition of classical complement activation by
membrane-bound and circulating control
proteins; Disappearance of cleaved component
C4c and stable binding of fragment C4d
mediated by the internal thioester; (Compiled
from [61, 62, 66—68]).
studies, the time interval during which immune deposits on
endothelial cells can be detected ranges from three to four days.
This time course is of clinical relevance since deposition of
preformed antibodies immediately after transplantation would be
missed in biopsies performed beyond four days. As the onset of
immunologic injury typically predates the clinical signs of rejec-
tion, biopsies in general may be performed too late for the
detection of humoral attacks.
The diagnostic yield can be improved when more stable mark-
ers of humoral immune reactions are explored. Activation of
complement via the classical, that is, antibody-induced pathway
generates the small fragment C4d that can bind covalently to
tissues [671. In contrast to the widely examined C4c component,
which is rapidly removed, the C4d fragment resists shedding and
also leaves a persistent imprint in capillaries (Fig. 4B). Thus,
immunohistological demonstration of capillary deposition of C4d
in biopsies can reveal otherwise undetectable humoral anti-graft
reactions (Fig. 5) [681. Using this technique, abundant vascular
deposition of complement C4d was found in 45% of grafts
affected by the complex syndrome of "early dysfunction." Impor-
tantly, the outcome of grafts showing capillary C4d was signifi-
cantly worse (57% surviving at 1 year) than the outcome of grafts
without detectable C4d (90% surviving) [69]. In addition to early
graft dysfunction, involvement of classical complement activation
could also he demonstrated in a high proportion of grafts with
longer function having acute steroid-resistant or chronic rejec-
tions. Interestingly, the immunohistological presentation of cap-
illaiy complement deposition was paralleled by an increased
urinary excretion of soluble C4d [70].
It should be mentioned that the capillary deposition of comple-
ment fragment C4d is not associated with obvious morphological
changes in the affected endothelia. Other studies have shown that
the deposition of non-lytic amounts of the terminal complex
C5b-9 also leaves the endothelium intact. However, transient
immune reactions can lead to endothelial activation [711 and to a
reversible perturbation of endothelial integrity and intermittent
loss of barrier function [721. Thus, alterations in endothelial
function are likely to escape histological detection by light micros-
copy.
The detection of capillary complement C4d in a high propor-
tion of biopsies prompts us to conclude that the incidence of
humoral alloreactions may have been underestimated in the past.
Analysis of HLA class H-reactive alloantibodies in vitro
Humoral immune reactions that leave imprints of C4d in
biopsies should be detectable in the circulation. However, a series
of problems is encountered also in the assessment of circulating
alloreactive antibodies.
Several in vitro assays have been developed for the detection of
alloantibodies in serum specimens. They are used to determine
the level of overall sensitization ("panel-reactivity") and of donor-
specific reactivity ("crossmatch") in recipients. The microcytotox-
icily test, as described by Terasaki and McClelland [731, has
become the most widely used assay because of its simplicity and
reliability. It is based on the attachment of serum antibodies to
target cells and their subsequent lysis by xenogeneic complement.
Consequently, antibodies that fail to induce complement-medi-
ated lysis, for example, because of low antibody titers, antibody
isotype, or because of relative target cell resistance to comple-
ment, will not be detected. To improve the sensitivity of the assay,
several modifications have been introduced aiming to enhance
antibody-binding and complement-mediated target lysis [74]. The
requirement for cytotoxicity is avoided with cytofluorimetric tech-
niques that detect antibody-binding to target cells by indirect
immunofluorescence. These techniques have very high sensitivity
and can detect low-titer antibodies. Using additional labels in
A
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Fig. 5. Assessment of humoral rejections in graft biopsies. (A) Presence of C4d in glomerular and peritubular capillaries indicating humoral anti-graft
reaction; (B) Absence of capillaiy C4d suggesting predominant cell-mediated rejection; (Immunoperoxidase staining, mAb M4d2 reactive against
fragment C4d; magnification x 120). Publication of this figure in color was made possible by a grant from Sandoz AG, NUrnberg, Germany.
two-color flow cytometry, the target cells [75] or antibody activity
in terms of complement activation can be characterized in more
detail [76]. Highly sensitive ELISA-techniques also use immobi-
lized HLA molecules bound to microtiter plates [77].
Various target cells or their antigens can be used in any of the
assays described. The selection of target cells, determining the
specificity of alloantibodies that will be detected, therefore de-
serves attention.
The ideal test targets would be allogeneic endothelial cells
representing the primary in vivo targets [42]. However, laborious
preparation and difficulties with in vitro propagation limit the
supply of endothelial cells. As a major drawback, the antigenic
profiles of endothelial cells are different in vivo and in vitro. Thus,
endothelial cells in culture do not display HLA class II molecules
[78] unless stimulated by IFN-y. Endothelial cells therefore are
infrequently used for antibody testing. As a substitute, epidermal
cells were used recently in immunofluorescence and flow cytomet-
nc studies 179].
The pre-existing "humoral risk" of an individual recipient, in
terms of "panel-reactivity," is usually assessed with peripheral
lymphocytes derived from HLA-typed unrelated blood donors. In
crossmatch tests, donor-specific cells are mostly obtained from
spleen or lymph node. Since cell preparations from peripheral
blood, and also from spleen or lymph node may not contain
sufficient numbers of cells bearing HLA class II, these tests fall
short in their ability to recognize all class Il-reactive antibodies.
B-lymphocytes, chronic lymphocytic leukemia cells or EBV-trans-
formed lymphoblastoid cell lines (LCL) are often used for the
detection of anti-class II antibodies. In flow cytometry testing,
however, B-lymphocytes may produce unfavorable background
due to the constitutive expression of surface immunoglobulins.
Background staining is less a problem with long-term cultures of
EBV-transformed LCL. With a representative collection of ho-
mozygous, DR-typed LCL, antibodies against a broad spectrum of
HLA class II determinants can he readily detected. Thus, by
cytofluorimetric analysis, LCL-reactive antibodies were present in
51% of recipients that subsequently developed "early graft dys-
function" and by far exceeded the 23% incidence of patients with
conventional "panel-reactive" antibodies [76]. That such pre-
formed antibodies do not simply reflect an enhanced overall
immune reactivity but rather are reactive specifically in vivo, could
be demonstrated by their association with capillary C4d in corre-
sponding graft biopsies. Since multiple determinants are ex-
pressed on the cell surface of LCL, specific anti-class II reactivity
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Fig. 6. Specific anti-DR reactivity of patient sera determined by Western blot
analysis of lysates from DR-typed LCL. Lane 1, mAb W.6.32 reactive
against HLA class I; lane 2, mAb L.2.43 reactive with a band of mol.wt.
56kd representing HLA-DR; lanes 3, 4, patient sera reacting with HLA-
DR; lane 5, nonreactive patient serum; (10% SDS-PAGE, nonreducing
conditions).
has to be confirmed by subsequent analysis. In the study cited,
anti-DR reactivity of antibodies could be verified in selected cases
by FACS-analysis with mouse fibroblasts transfected with human
DR3 and by Western blot analysis of LCL lysates (Fig. 6). In other
studies, anti-class II reactivity could be identified using prepara-
tions of soluble or immobilized HLA molecules [80, 81]. The
future availability of representative HLA-transfectants [82] and
recombinant class II molecules should facilitate detailed analyses.
The use of various target cells, combined with highly sensitive
flow cytometric methods, has extended the spectrum of detectable
alloreactive antibodies. In the setting of crossmatch testing, these
techniques meanwhile have generated uncertainty, as not all
detectable antibodies may be clinically relevant. Consequently,
the clinical usefulness of B-cell crossmatches is debated [831. It is
generally accepted that anti-B-cell antibodies of the 1gM type are
innocuous whereas IgG antibodies appear to be deleterious,
especially if they are directed against class II HLA-DR specifici-
ties. The situation is complicated by the fact that an apparent
B-cell specific reactivity in the standard crossmatch assay may
result from weak anti-class I antibodies because B-cells express
surface class I antigens with higher density than T-cells [84]. The
sensitivity of B-cell crossmatches can be further increased using
flow cytometry [75]. Crossmatch tests with very high sensitivity
may prevent some graft failures, hut on the other hand they may
also preclude the performance of potentially successful transplan-
tations. Therefore, the potential hazard conveyed by various
alloantibodies needs to be defined more precisely. Until this issue
is settled it seems justified to confine conventional B-cell cross-
matches to IgG reactivity measured at 37°C. The predictive value
of B-cell crossmatches appears to be greater in retransplants than
in first transplants, especially when preformed panel-reactive
antibodies are present in the recipient's serum (Fig. 7) [85].
The assessment of humoral sensitization in the post-transpian-
tation period represents another unresolved task. Given the high
rate of sensitization even in recipients of first grafts, it is somewhat
surprising that sera are exhaustively screened before but not after
transplantation. A detailed analysis of humoral responses could
well provide further clues to the pathogenesis of chronic rejection
and may also provide a basis for immunomodulatory interventions
97 kDa [86, 87].
Recent studies with alloreactive T-cells have addressed the role
of HLA-bound peptides in directing specificity and maintenance
of cellular alloreactivity [88]. The role of peptides will also have to
— 69 kDa be considered in future studies on the diversity of humoral
alloreactivity. Each MHC molecule can bind many different
peptides, thereby undergoing peptide-dependent conformational
changes. Antibodies therefore may recognize different conforma-
tions of MHC/peptide complexes and they may also recognize
peptides directly [89]. Thus, for class I and class II molecules an
— 46 kDa influence of the peptide ligand on the binding of monoclonal
antibodies has already been shown [90—92]. It will be interesting
to determine whether peptide heterogeneity within HLA mole-
cules likewise affects alloreactivity of patient sera.
Immunopathological consequences of humoral anti-graft
reactions and therapeutic considerations
Several consequences of transient antibody deposition and
vascular complement activation in allografts have to be consid-
ered. Deposited antibodies can interact with surface Fc-receptors
on circulating mononuclear cells, lead to the accumulation and
adhesion of infiltrating leukocytes and induce cell-mediated cyto-
toxic reactions [93]. Especially complement will promote such
interactions at several stages of activation, including the genera-
tion of anaphylatoxins such as C3a and C5a, and the deposition of
adhesive proteins such as iC3b on endothelial surfaces. Since
complement split products can stimulate human T- and B-
lymphocytes, lymphocyte activation within a graft might be influ-
enced. Complement factors could also interfere with the coagu-
lation system and thereby contribute to occlusive vasculopathy in
acute and chronic rejections [60, 94]. It has yet to be determined
whether antibodies reactive against HLA class II determinants
can also up-regulate the expression of endothelial adhesion
molecules, as was shown for class I-reactive antibodies [95, 96].
Similarly, the release of TNF-a following cross-linking of HLA
class II molecules, as shown with EBV-transformed lymphoblas-
toid cell lines [97, 98], could promote graft rejection.
At present, humoral transplant rejections are difficult to treat,
with only few therapeutic options available. Preformed antibodies
in recipients may be removed by plasmapheresis or immunoad-
sorption [99] to allow a crossmatch-negative transplantation, yet
the long-term success of such maneuvers remains questionable
[100]. The clinical efficacy of high-dose intravenous immuno-
globulins still has to be shown [101]. With regard to the commonly
used immunosuppressants such as steroids, cyclosporine or aza-
thioprine, it should be remembered that none of them is specifi-
cally active against B-lymphocytes. Some beneficial effect in the
treatment of vascular rejections might be derived from their
ability to down-regulate adhesion molecules [102] and MHC class
II molecules [17]. It is also worth noting that cyclophosphamide,
a strong inhibitor of B-cell proliferation [103], is not widely used
in organ transplantation.
The low efficacy of current therapies in the suppression of
humoral immune responses may well he a reason that long-term
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Fig. 7. Clinical relevance of conventional B-cell crossmatches in cadaver
kidney grafts. The tests were performed at 37°C. At this temperature most
positive crossmatches are attributable to EgG antibodies. The influence of
positive B-cell crossmatches is statistically significant both in first trans-
plants (P <0.001) and in retranspiants (P < 0.001). The reduction in graft
survival attributable to positive B-cell crossmatches is greater in retrans-
plants (ReTx) than in first transplants, especially in patients with pretrans-
plant panel-reactive antibodies (>10% Ab). Data source: Collaborative
Transplant Study. Symbols are: (S") B— first Tx, N = 31821; (- - - -) B+
first Tx, N = 2024; ( ) B— ReTx, N = 5612; ('— - —-) B+ ReTx, N =
786; (————) B+ ReTx > 10% Ab, N = 434.
graft survival did not improve during the last decade. It is to be
hoped that some of the new drugs that are evaluated at present in
clinical trials will also effectively inhibit the humoral immune
system.
Conclusion
In our effort to identify determinants of the heterogeneity of
renal transplant rejection, we found the influence of the HLA-DR
complex to be of greatest interest. Histocompatibility at this locus
is of prime importance because class II molecules are normally
expressed on human endothelial cells in vivo, and thus contribute
to the exquisite immunogenicity of graft vessels and form primary
targets for both cellular and humoral immunological attacks.
Manifestations of humoral anti-graft reactions may, however, be
elusive compared to the easily detectable cell-mediated rejections.
Their comprehensive assessment in biopsies as well as in serum
samples requires the application of refined diagnostic techniques.
If properly assayed, the incidence of humoral alloreactions is
much higher than previously thought. On that basis we would like
to challenge the commonly accepted overwhelming predominance
of cell-mediated immunity in graft rejection and the resulting
simplistic concept of current immunosuppression. Instead, we
suggest that the heterogeneity of renal allograft rejection may be
critically determined by the dynamic forces of humoral immunity.
Detailed analysis of humoral sensitization in the pre- and post-
transplantation period, therefore, would seem a most worthwhile
task. This knowledge will be important for the judicious selection
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of appropriate immunosuppressive therapies that inhibit humoral
immunity and hopefully will lead to improved, long-term graft
survival.
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